IQWiG finds no added benefit for Columvi in late-line lymphoma

Germany’s Institute for Quality and Efficiency in Health Care concluded that Columvi (glofitamab) monotherapy shows no added benefit for adults with relapsed or refractory diffuse large B-cell lymphoma treated from third line. IQWiG said the manufacturer submitted no suitable comparative evidence against the therapies defined by Germany’s benefit framework.

IQWiG’s review covered patients eligible and ineligible for advanced options such as CAR-T or transplant. The dossier relied on single-arm data rather than randomized trials aligned to Germany’s specified comparators. IQWiG noted a recent update to those comparators, further limiting the ability to draw conclusions on added benefit.

The ruling now feeds into Germany’s pricing and reimbursement process, where the Federal Joint Committee will decide next steps. A “no added benefit” finding typically tightens negotiation leverage. Roche (ROG: SIX) can submit new evidence or comparative data to revisit the assessment in future proceedings.